HealthLynked Launches National Initiative to Accelerate Medical Discovery Through Patient Participation and Strategic Pharma Partnerships

HealthLynked Launches National Initiative to Accelerate Medical Discovery Through Patient Participation and Strategic Pharma Partnerships

NAPLES, Fla., Aug. 5, 2025 /PRNewswire/ --  HealthLynked Corp. (OTCQB: HLYK), a healthcare technology company connecting patients, providers, and data, today announced a nationwide initiative to make patients central collaborators in medical research—and to help pharmaceutical, biotech, and academic partners accelerate discovery using HealthLynked's patient network and AI capabilities. With over 1 million registered members, HealthLynked can enable large-scale, consented participation to advance prevention, earlier diagnosis, and more effective treatments. These programs will be rolled out over the next six months as HealthLynked formalizes research partnerships, with initial capabilities beginning in Q3 2025, expanded modules in Q4 2025, and full program availability targeted by January 2026.

Founded by physician and healthcare entrepreneur Dr. Michael Dent, who also founded NeoGenomics Laboratories, HealthLynked was created to empower patients and speed the search for cures for life-threatening diseases and cancers. Today's initiative advances that mission by opening clearer, simpler on-ramps for patients to contribute—and by offering research partners structured programs to generate high-quality real-world evidence.

"Most people want to help cure diseases but have very few practical opportunities to do so," said Dr. Dent, CEO of HealthLynked. "By creating a free profile, patients can securely share their health history, opt into studies, and get matched to relevant trials—while our partners gain the real-world evidence they need to move faster from hypothesis to impact."

How Patients Help—and Benefit

Through the free HealthLynked profile, patients can:

• Enter medical history (conditions, medications, procedures, family history) and opt in to research participation.
• Receive personalized notifications—such as trial matches, safety alerts, recall notices, and trend-based insights tied to their health history.
• Contribute patient-reported outcomes (ePROs) and longitudinal updates that help researchers understand disease progression and treatment effectiveness in real-world settings.

All research activity is consent-driven, with data de-identified or aggregated when appropriate, and studies conducted under applicable privacy and ethics requirements (including HIPAA and IRB oversight where required).

Partner Programs for Pharma, Biotech, and Academia

HealthLynked is launching structured collaboration tracks to support the full research lifecycle:

1.  Cohort Finder & Feasibility – Rapid identification of consented patient cohorts meeting complex inclusion/exclusion criteria; feasibility assessments across geographies.

2.  Recruitment & eConsent – Digital outreach, screening, and IRB-aligned eConsent workflows; optional decentralized trial support.

3.  ePROs & RWE Generation – Collection of longitudinal patient-reported outcomes and integration of real-world data to inform endpoints, labeling, and health-economics studies.

4.  Signal & Safety Monitoring – Post-marketing surveillance, device and medication safety signal detection, and recall communication to relevant patient segments.

5.  Natural History & Rare Disease Registries – Patient-powered registries to understand disease trajectories and support companion diagnostic development.

Six-Month Rollout: These collaboration tracks will be phased in over the next six months as HealthLynked develops and finalizes research partnerships with pharmaceutical sponsors, biotech firms, and academic medical centers—starting in Q3 2025, expanding in Q4 2025, with general availability targeted by January 2026.

ARi: HealthLynked's AI Healthcare Agent

HealthLynked's ARi—built with advanced OpenAI technologies—helps synthesize patient-contributed data to highlight population trends and individual risk signals. ARi aids in feasibility modeling, cohort refinement, and predictive insights that can shorten timelines for study design, trial recruitment, and evidence development. For patients, ARi supports personalized health alerts based on emerging patterns and their own medical history.

A Call to Action

Patients: Join for free, contribute to research, and receive informed insights about your health.
Researchers & Sponsors: Partner with HealthLynked to speed feasibility, recruitment, and RWE generation. Program access will expand throughout the next six months as partnerships are executed.

For those wishing to make an even greater impact, HealthLynked offers premium memberships at $12/month, including enhanced features, discounted telemedicine services, and priority access to the provider network.

"Imagine if everyone affected by cancer, Alzheimer's, or heart disease could actively participate in finding a cure," added Dr. Dent. "That's the network we're building—a national, and eventually global, research engine powered by patients."

Partnership Opportunities

Organizations interested in joining HealthLynked in its mission to accelerate medical discovery through collaboration and innovation can learn more and connect with the company at www.hlykgroup.com.

About HealthLynked Corp.
HealthLynked Corp. is transforming the future of healthcare through a cloud-based platform that connects patients, physicians, and researchers. HealthLynked provides telemedicine, medical record sharing, discounted prescriptions, and AI-powered health tools to improve outcomes and make care more accessible. With a focus on personalized care and large-scale data insights, HealthLynked empowers individuals to take control of their health while contributing to the advancement of medicine.

To join or learn more, visit www.hlykgroup.com

Download the HealthLynked App:

• Apple App Store
• Google Play Store

Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such statements are inherently uncertain and may differ materially from actual results. Forward-looking statements reflect management's current expectations and are subject to risks, uncertainties, and assumptions. HealthLynked disclaims any obligation to update these statements except as required by law.

Investor  & MediaContact

HealthLynked Corp.
1265 Creekside Parkway, Suite 200
Naples, FL 34108
Phone: +1 (800) 928-7144
Email: [email protected]

SOURCE HealthLynked Corp.